Glenmark Pharmaceuticals receives final approval for Nitroglycerin Sublingual Tablets

From USFDA

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg, of Pfizer, Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market achieved annual sales of approximately $112.7 million.

Powered by Capital Market - Live News